Dronedarone Hydrochloride

Dronedarone Hydrochloride is a Class III antiarrhythmic drug that works to restore normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. As a non-iodinated benzofuran derivative, Dronedarone Hydrochloride was developed to overcome the iodine-associated adverse effects of the structurally related antiarrhythmic agent amiodarone. Dronedarone Hydrochloride is a multi-channel blocker that inhibits potassium, sodium, and calcium channels and also exhibits antiadrenergic properties, helping to restore and maintain normal cardiac rhythm. Structurally, Dronedarone Hydrochloride is related to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. In pharmaceutical quality control contexts, Dronedarone Hydrochloride serves as both the active pharmaceutical ingredient for Multaq® manufacturing and as a reference standard for analytical method development and impurity profiling.

 

 Product Parameters

---

Parameter	Specification
Product Name	Dronedarone Hydrochloride
CAS Number	141625-93-6
Molecular Formula	C₃₁H₄₄N₂O₅S·HCl
Molecular Weight	593.22 g/mol
Appearance	White to off-white powder
Polar Surface Area	88.85 Ų
Solubility	DMSO: 15 mg/mL, clear
Storage Condition	2–8 °C

 

Indication

---

Dronedarone Hydrochloride is an antiarrhythmic agent indicated for patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), those at risk of hospitalization due to recent AF/AFL episodes or with cardiovascular risk factors, as well as patients with sinus rhythm or rhythm that can be restored by cardioversion.

 

Pharmacokinetics

---

The elimination half-life of decanedalone hydrochloride is 24 hours, whereas that of amiodarone ranges from 30 to 50 days. Decanedalone exhibits low bioavailability (only 15%–20%) due to significant hepatic first-pass effect; co-administration with food can increase its plasma concentration by 2–3-fold. Following oral administration, decanedalone is primarily metabolized via CYP3A4, and thus drugs with CYP3A4-inhibiting activity (e.g., ketoconazole, calcium channel blockers) may elevate its plasma concentration. Similarly, decanedalone moderately inhibits CYP2D6 activity, leading to increased plasma concentrations when co-administered with metoprolol or propranolol; therefore, dosage adjustment is required during combination therapy. Additionally, only approximately 6% of decanedalone is renally eliminated, meaning its plasma concentration is not affected by renal function.

 

Synthetic Route

---

The preparation method of desonidalone hydrochloride involves the following specific steps:

(1)In an organic solvent, 2-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran was etherified with 1-bromo-3-chloropropane to yield 2-n-butyl-3-[4-(3-chloropropoxy)benzoyl]-5-nitrobenzofuran;

 

(2)Reduce it with a reducing agent to 2-n-butyl-3-[4-(3-chloropropoxy)benzoyl]-5-amino-benzofuran;

 

(3)The sulfonamidation reaction with methyl sulfonyl chloride in an organic solvent yields 2-n-butyl-3-[4-(3-chloropropoxy)benzoyl]-5-methanesulfonylamidobenzofuran;

 

(4)Then, a N-hydrocarbon reaction with 2-butanethanolamine is carried out to obtain desonidalone;

 

(5) Desonidalone undergoes a salt formation reaction to yield desonidalone hydrochloride.

 Contact Us

---

Need Dronedarone Hydrochloride for your antiarrhythmic manufacturing campaign, analytical method development, or regulatory filing? Cosperpharm is your trusted partner for high-purity API and reference standards. Reach out today—our team is ready to support your project from R&D through commercial production.